Aciont
Envisioning the Future of Ocular Therapeutics
About Us | Unmet Needs | Technologies | Product Pipeline | Media & Investors
Product Pipeline

Potential Customers

Visulex® will be attractive to both physicians and patients of ophthalmic therapeutic administrations. Our products will be priced competitively and are expected to gain wide acceptance through the following: better safety for both medical staff and patients; ease of preparation and use requiring minimal training; productivity/timeliness and comfort of administration; and superior efficacy and therapeutic control.

In the United States, roughly 2,000 retinal specialists comprise a viable marketing channel for administering to patients our Visulex®-based products. However, physician assistants or nurses (trained clinical staff) or optometrists potentially may administer Visulex's non-invasive treatments, whereas intraocular injections, for example, must be administered as required by law by the physician. Also, self administration of Visulex® products could be possible as a long term objective.